Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Dinesh, De"'
Autor:
Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs
Publikováno v:
PLoS ONE, Vol 19, Iss 11, p e0309778 (2024)
Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with previous standard dosing of 200 mg or 2 mg/kg every 3 weeks, and early results of cohort B of the
Externí odkaz:
https://doaj.org/article/160650ac9b154127a4ad18e487432848
Autor:
Zinnia P. Parra-Guillen, Tomoko Freshwater, Youfang Cao, Kapil Mayawala, Sara Zalba, Maria J. Garrido, Dinesh de Alwis, Iñaki F. Troconiz
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
V937 is an investigational novel oncolytic non-genetically modified Kuykendall strain of Coxsackievirus A21 which is in clinical development for the treatment of advanced solid tumor malignancies. V937 infects and lyses tumor cells expressing the int
Externí odkaz:
https://doaj.org/article/fe7a797feed243a7b7e33bf75654da34
Autor:
Marianne J. H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef, Ellen S. Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth H. Robey, Anna G. Kondic, Dinesh De Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the developm
Externí odkaz:
https://doaj.org/article/3069c7c4e0f64562b9cab9bff16d3f3d
Autor:
Olga Marchenko, Rajeshwari Sridhara, Qi Jiang, Elizabeth Barksdale, Yuki Ando, Dinesh De Alwis, Katie Brown, Laura Fernandes, Mark T. J. van Bussel, Qiuyi Choo, Michael Coory, Elizabeth Garrett-Mayer, Thomas Gwise, Lorenzo Hess, Rong Liu, Sumithra Mandrekar, Daniele Ouellet, José Pinheiro, Martin Posch, Nam Atiqur Rahman, Khadija Rerhou Rantell, Andrew Raven, Sarem Sarem, Suman Sen, Mirat Shah, Yuan Li Shen, Richard Simon, Marc Theoret, Ying Yuan, Richard Pazdur
Publikováno v:
Statistics in Biopharmaceutical Research. :1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e45310ce9d3649ab6576517e025f0859
https://doi.org/10.1080/19466315.2023.2166099
https://doi.org/10.1080/19466315.2023.2166099
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Autor:
Zinnia P Parra‐Guillén, Aymara Sancho‐Araiz, Kapil Mayawala, Sara Zalba, Maria J Garrido, Dinesh de Alwis, Iñaki F. Troconiz, Tomoko Freshwater
Publikováno v:
Clinical Pharmacology & Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bdfcb753c6cb6ff10d883fd390c210c
https://doi.org/10.1002/cpt.2937
https://doi.org/10.1002/cpt.2937
Autor:
Kapil, Mayawala, Dinesh, de Alwis
Publikováno v:
Pharmaceutical Research. 39:1817-1822
After a drug molecule enters clinical trials, there are primarily three levers to enhance probability of success: patient selection, dose selection and choice of combination agents. Of these, dose selection remains an under-appreciated aspect in onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b1f2e873b43f9ff9491727529c1057
https://doi.org/10.1007/s11095-022-03263-5
https://doi.org/10.1007/s11095-022-03263-5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
European Journal of Chemistry. 13:1-7
We report the synthesis, characterization, X-ray crystal structure and Hirshfeld surface analysis of Ni(II) perchlorate complex (1, Ni2L3·4ClO4·2CH3CN) of 1,2-bis(pyridin-2-ylmethylene)hydrazine (L) ligand. The X-ray crystallographic study of compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0f92efb9e7c06bdd2dc4ecbd71cad7e
https://doi.org/10.5155/eurjchem.13.1.1-7.2166
https://doi.org/10.5155/eurjchem.13.1.1-7.2166
Autor:
Goutam Kumar Patra, Dinesh De
Publikováno v:
European Journal of Chemistry. 13:49-55
The synthesis, characterization, and theoretical studies of the title compound has been reported in this study. The molecular structure has been characterized by room-temperature single-crystal X-ray diffraction study which reveals that it has an ang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7203615161858f191765faf19afa1516
https://doi.org/10.5155/eurjchem.13.1.49-55.2175
https://doi.org/10.5155/eurjchem.13.1.49-55.2175